# A Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)

> **NCT01242111** · PHASE1,PHASE2 · TERMINATED · sponsor: **BioMarin Pharmaceutical** · enrollment: 20 (actual)

## Conditions studied

- MPS IV A
- Mucopolysaccharidosis IVA
- Morquio A Syndrome

## Interventions

- **DRUG:** BMN 110

## Key facts

- **NCT ID:** NCT01242111
- **Lead sponsor:** BioMarin Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-11
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2015-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01242111

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01242111, "A Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01242111. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*